mRNA vaccines trigger better response in cancer patients

Of 211 cancer patients included in a study coordinated by the Instituto Gulbenkian de Ciência (IGC) and the Hospital Professor Doutor Fernando Fonseca E.P.E., 43% developed antibodies after the first dose of the vaccine against COVID-19, increasing to 83% after complete vaccination. However, the percentage of patients who developed antibodies during this period varied according to the vaccine that was administered and the type of treatment they were undergoing.

Check the latest news in the press about this study (in Portuguese):

in RTP

in Expresso 

in Observador

Updated on 17 november 2021